Mono- and binuclear ruthenium(II) complexes containing ligands derived from the meta-bis(phosphanyl)arene ligand 1-R-3,5-(CH2PPh2)2C6H3 [R−PCHP: R = H (5), Br (3), or Si(n-CH2CH2C8F17)3 (4)] have been synthesized and fully characterized. On reaction of equimolar amounts of the ruthenium starting material (e.g. [RuCl2(PPh3)3]) and the meta-bis(phosphanyl)arene, complexes of the type [RuCl{C6H2(CH2PPh2)2-2,6-R-4}(PPh3)] are invariably isolated, which contain only one [C6H3(CH2PPh2)2-2,6]− monoanionic ligand η3-P,C,P′-bonded to Ru. Monitoring of this reaction by 1H and 31P NMR has shown it to proceed via intermediate species having an apparently η3-P,C,P′-bonded PCP ligand and a second meta-bis(phosphanyl)arene ligand that is either η1-P-bonded or μ-η1-P,η1-P′-bridging between two [RuCl(PCP)] units. The synthesis of the first PCP “pincer”-type ligand with a polyfluorinated “pony tail” is detailed, viz. compound 4 as well as the corresponding ruthenium complex [RuCl{(n-C8F17CH2CH2)3Si−PCP}], 7. The latter compound is soluble in fluorinated solvents and hence represents the first ruthenium “pincer” complex that may find use in fluorinated biphasic systems.
No takes yet. Share an insight, caveat, or question.
Dani et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: